Analyst Robert Burns works at HCWAINWRIGHT and is focused on the Healthcare sector with 217 price targets and ratings documented since 2019 spanning on 25 stocks. Analyst's average stock valuation to be materialised ratio is 22.66% with an average time for price targets to be met of 50.59 days.
Most recent stock forecast was given on FATE, Fate Therapeutics, Inc at 24-Jan-2023.
Robert Burns best performing recommendations are on ZYME (ZYMEWORKS INC).
The best stock recommendation documented was for ZYME (ZYMEWORKS INC) at 1/4/2023. The price target of $8 was fulfilled within 1 day with a profit of $0.33 (4.3%) receiving and performance score of 43.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
30
$17.13 (133.10%)
50
8 months 17 days ago
0/4 (0%)
$20.92 (103.21%)
Buy
48
$35.13 (272.96%)
49
9 months 18 days ago
0/4 (0%)
$27.01 (133.48%)
Buy
45
$31.97 (245.36%)
1 years 11 days ago
0/1 (0%)
$23.08 (105.29%)
